To assess whether c-aminobutyric acid (GABA) modulation of dopamine is important in mediation of the discriminative stimulus effects of methamphetamine, the GABA compounds chlordiazepoxide (benzodiazepine site agonist), pentobarbital (barbiturate site agonist), bicuculline and pentylenetetrazol (GABA A receptor antagonists) were tested in Sprague-Dawley rats trained to discriminate methamphetamine (1 mg/kg, i.p.) from saline. Each of the compounds produced modest amounts of methamphetamine-appropriate responding (20-35%) when tested alone. When tested in combination with methamphetamine, the antagonists (bicuculline and pentylenetetrazol) failed to shift the methamphetamine dose-effect curve. In contrast, chlordiazepoxide (25 mg/kg, i.p.) reduced methamphetamine-appropriate responding at each dose of methamphetamine tested, and pentobarbital (10 mg/kg, i.p.) dose-dependently decreased the discriminative stimulus effects of 1 mg/kg methamphetamine. In conclusion, GABA A antagonists and positive modulators likely do not produce methamphetamine-like stimulus effects. However, activation of GABA A receptors can interfere with the discriminative stimulus effects of methamphetamine.
Introduction
Methamphetamine has increasingly become an significant drug of abuse, as its use has increased in various regions of the US (National Institute on Drug Abuse, 2002) . However, the behavioral effects of methamphetamine are not nearly as well-characterized as those of other psychostimulants. The drug discrimination studies that have been conducted in rats and monkeys have largely characterized the role of monoaminergic systems in mediating the discriminative stimulus effects of methamphetamine. Not surprisingly, given the well-known role of methamphetamine as a releaser of dopamine (Gerasimov et al., 1999) , dopamine (DA) releasers, uptake inhibitors, and D 1 -like and D 2 -like receptor agonists all substitute for the discriminative stimulus effects of methamphetamine (Tidey and Bergman, 1998; Munzar et al., 1999a; . Conversely, antagonists of D 1 and D 2 receptors block the methamphetamine discriminative stimulus (Tidey and Bergman, 1998; .
The discriminative stimulus effects of methamphetamine seem to be most closely associated with dopaminergic neurotransmission, as adrenergic and serotonergic compounds have only modest effects. Indeed, adrenergic and serotonergic uptake inhibitors do not substitute for methamphetamine (Tidey and Bergman, 1998; Munzar and Goldberg, 1999; Munzar et al., 1999a) , and b-adrenergic compounds fail to substitute or block the stimulus effects of methamphetamine (Munzar and Goldberg, 1999) . a2-adrenergic compounds and various serotonin (5-HT) agonists (5-HT 1A , 5-HT 2 , 5-HT 3 ) produce at best partial substitution or small leftward shifts in the dose response for methamphetamine discrimination (Munzar and Goldberg, 1999; Munzar et al., 1999b Munzar et al., , 2002 .
To date, the role of GABA A receptors in the mechanism for the discriminative stimulus effects of methamphetamine has not been studied. This is a potentially interesting line of investigation because GABA mediates/modulates the actions of dopamine receptors in the central nervous system. For example, the increase in DA release induced by methamphetamine is blocked by gamma-vinyl GABA (Gerasimov et al., 1999) , and interneurons in the ventral tegmental area are known to regulate DA release in the nucleus accumbens (Xi and Stein, 1998; Rahman and McBride, 2002) . Conversely, DA inhibits GABA transmission, and this effect is absent in D 2 -receptor knockout mice (Centonze et al., 2003) . GABA A and DA D 5 receptors can form a heteromeric complex in the hippocampus, which suggests a coregulatory role of these two receptors (Agnati et al., 2003) . It is interesting to note that the GABA B agonist baclofen failed to substitute for or block the stimulus effects of methamphetamine . However, the failure of a GABA B compound to alter the stimulus effects of methamphetamine does not preclude the possibility that GABA A receptors may contribute. Clonazepam, which activates GABA A receptors through its actions at the benzodiazepine receptor, prevents the development of sensitization to the locomotor effects of methamphetamine (Ito et al., 1997) , which supports the possibility that GABA A receptors may play a more active role in modulating the behavioral effects of dopaminergic compounds than GABA B receptors.
The present experiments examined the actions of GABA A receptor selective compounds on the discriminative stimulus effects of methamphetamine in rats. The GABA A receptor antagonists pentylenetetrazol and bicuculline, and the allosteric GABA A receptor agonists chlordiazepoxide and pentobarbital, were tested alone and in combination with methamphetamine in rats trained to discriminate methamphetamine (1 mg/kg) from saline.
Methods

Subjects
Male Sprague-Dawley rats were obtained from HarlanSprague Dawley (Indianapolis, Indiana, USA). All rats were housed individually and were maintained on a 12:12 light/dark cycle (lights on at 07.00 hours). Body weights were maintained at 320-350 g by limiting food to 20 g/day, which included the food received during operant sessions. Water was freely available. All housing and procedures were in accordance with the guidelines of the Institute of Laboratory Animal Resources, National Research Council (Institute of Laboratory Animal Resources, 1996) and were approved by the University of North Texas Health Science Center Animal Care and Use Committee.
Discrimination training
Standard operant chambers (Coulbourn Instruments, Allentown, Pennsylvania, USA) were connected to IBM-PC compatible computers via LVB interfaces (Med Associates, East Fairfield, Vermont, USA). The computers were programmed in MED-PC 1.15 (Med Associates) for the operation of the chambers and collection of data.
Rats were trained to discriminate methamphetamine (1 mg/kg) from saline using a two-lever choice methodology. Food (45 mg food pellets; Bio-Serve, Frenchtown, New Jersey, USA) was available as a reinforcer under a fixed-ratio 10 schedule when responding occurred on the injection-appropriate lever. There was no consequence for incorrect responses. The rats received approximately 60 training sessions before use in any behavioral experiment. Animals were selected for use in experiments when they had met the criteria of emitting 85% of responses on the injection-correct lever for both the first fixed-ratio and during the remainder of the session during their last 10 training sessions.
Training sessions occurred in a double alternating fashion (D-D-S-S-D, etc.), and tests were conducted between pairs of identical training sessions (i.e. between either two saline or two methamphetamine training sessions). Rats were tested only if they had achieved 85% drug-lever responding for both first fixed-ratio and total session on the two prior training sessions. Before each session, the rats received an injection of either saline or methamphetamine. Ten minutes later, the rats were placed in an operant chamber. Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets.
Test procedures
For all test sessions, i.p. injections of the test compounds or vehicle were given 15 min prior to the start of the test session. Intraperitoneal injections of the training dose of methamphetamine were given 10 min prior to the start of the test session. In contrast with training sessions, both levers were active, such that 10 consecutive responses on either lever led to reinforcement. Data were collected until the first reinforcer was obtained, or for a maximum of 20 min. At least 3 days elapsed between test sessions. Groups of 9 or 10 rats were tested with each test compound. A repeated measures design was used, such that each rat was tested at all doses in ascending order.
During substitution testing, bicuculline (0.5, 1.0, 2.5, 5.0 mg/kg), pentylenetetrazol (1.0, 2.5, 5.0, 10 mg/kg), chlordiazepoxide (1.0, 2.5, 5.0, 10, 25, 50 mg/kg), pentobarbital (5, 10, 25 mg/kg), or methamphetamine (0.1, 0.25, 0.5, 1 mg/kg) were tested for the ability to substitute for the discriminative stimulus effects of 1 mg/kg methamphetamine. Bicuculline (2.5 g/kg), pentylenetetrazol (10 mg/kg), chlordiazepoxide (5, 10, 25 mg/kg), and pentobarbital (10, 25 mg/kg) were also tested for the ability to antagonize the discriminative stimulus effects of the training dose of methamphetamine (1 mg/kg). The maximum dose of each compound was also tested in combination with the full dose range of methamphetamine (0.1-1 mg/kg). Test compounds were administered 15 min before testing, and methamphetamine (1 mg/kg) was administered 10 min before testing.
Drugs
Pentylenetetrazol (PTZ), bicuculline, chlordiazepoxide, and pentobarbital sodium were purchased from Sigma Chemical Co. (St. Louis, Missouri, USA). ( + )-Methamphetamine hydrochloride was obtained from the National Institute on Drug Abuse. Bicuculline was dissolved in deionized water. All remaining drugs were dissolved in 0.9% saline. All drugs were administered i.p. in a volume of 1 ml/kg.
Data analysis
Drug discrimination data were expressed as the mean percentage of responses made on the methamphetamineappropriate lever prior to completion of the first fixed ratio. Percent methamphetamine-appropriate responding and response rate were plotted as a function of the dose of the test compound (log scale). Percent methamphetamine-appropriate responding was calculated for a given dose only if at least 3 rats completed the first fixed ratio. Full substitution was defined as Z 80% methamphetamine-appropriate responding, and partial substitution as Z 40% and < 80% methamphetamine-appropriate responding. Rates of responding were expressed as a function of the number of responses made divided by the total session time. Comparison of the effects of various doses of pentobarbital and chlordiazepoxide in combination with methamphetamine was performed by one-way analysis of variance. Individual differences were compared using Duncan's Multiple Range Test. Criterion for significance was set a priori at P < 0.05.
Results
Substitution tests
GABA A antagonists pentylenetetrazol (n = 9) and bicuculline (n = 10) each failed to substitute for the discriminative stimulus effects of methamphetamine (Fig. 1) . Pentylenetetrazol produced a plateau of methamphetamine-appropriate responding at 30 to 35% methamphetamine-appropriate responding between 2.5 and 10 mg/kg. Seizures were observed in 3 of 9 rats following 10 mg/kg pentylenetetrazol. Bicuculline produced an increase in methamphetamine-appropriate responding to a maximum of 27% at a dose (5.0 mg/kg) that also produced seizures in 2 of 10 rats. There was no effect of either compound on response rates at the doses tested. Higher doses were not tested due to risk of seizures.
Pentobarbital (n = 10), a GABA A barbiturate-site agonist, produced no methamphetamine-appropriate responding at the doses tested (Fig. 2) . A dose-dependent decrease in response rates was observed, and the largest dose of pentobarbital (25 mg/kg) substantially decreased response rates such that only 1 of 10 rats completed the first fixed ratio. Chlordiazepoxide (n = 10), a GABA A benzodiazepine-site agonist, produced methamphetamine-appropriate responding which fluctuated between 17 and 33% in a dose range of 2.5 to 50 mg/kg (Fig. 2) . Chlordiazepoxide dose-dependently decreased response rates and progressively fewer rats completed the first fixed ratio, such that only 3 of 10 rats completed the first fixed-ratio following 50 mg/kg chlordiazepoxide.
Combination tests
Pentylenetetrazol (n = 10) and bicuculline (n = 10) both failed to modify the methamphetamine dose-effect curve (Fig. 1) . The maximum dose of PTZ (10 mg/kg) did not alter responding at any dose of methamphetamine. The maximum dose of bicuculline that did not produce seizures (2.5 mg/kg) also did not alter responding at any dose of methamphetamine (n = 10). Response rates after methamphetamine alone were not different from those when PTZ and bicuculline were combined with methamphetamine.
As shown in Fig. 2 , pentobarbital (10 mg/kg) decreased the effects of 0.25 and 1 mg/kg methamphetamine. In contrast, chlordiazepoxide (25 mg/kg, i.p.) reduced methamphetamine-appropriate responding at each dose of methamphetamine tested, except for the lowest dose of methamphetamine (0.1 mg/kg). Neither compound altered the response rate dose-effect curve produced by methamphetamine. Table 1 shows the effects of increasing doses of chlordiazepoxide or pentobarbital on the discriminative stimulus effects of the training dose of methamphetamine (1 mg/kg). There was an overall effect of dose [F(6,60) = 6.91, P < 0.001]. Pentobarbital dosedependently reduced the discriminative stimulus effects of methamphetamine to 63.6% (P < 0.05). Chlordiazepoxide produced a dose-dependent reduction to 42.5% (P < 0.05).
Discussion
No substitution for the discriminative stimulus effects of 1.0 mg/kg methamphetamine occurred with the GABA A antagonists (bicuculline and pentylenetetrazol) or the allosteric positive modulators of GABA A receptors (pentobarbital and chlordiazepoxide). Small increases in methamphetamine-appropriate responding occurred in all four compounds, but none reached the criterion for partial substitution of 40% drug-appropriate responding. These findings suggest that neither GABA A antagonists nor positive modulators produce methamphetamine-like stimulus effects. However, these two types of compounds differed in their effects when they were tested in combination with methamphetamine. The largest nontoxic doses of the GABA A antagonists failed to alter the methamphetamine dose-effect curve, showing neither antagonism nor facilitation of methamphetamine-lever responding. In contrast, pentobarbital and chlordiazepoxide both antagonized the discriminative stimulus effects of methamphetamine. Pentobarbital produced a small, but dose-dependent decrease in the discriminative stimulus effects of the training dose of methamphetamine (1 mg/kg), whereas chlordiazepoxide produced substantial decreases in methamphetamine-lever responding following 0.25-1 mg/kg methamphetamine.
The effects of these GABA A compounds on methamphetamine are different from those reported for cocainetrained rats and monkeys (Negus et al., 2000; Gatch et al., 2003) . In rats, GABA A compounds had no effect on the discriminative stimulus effects of cocaine, although diazepam may have produced a small facilitation of the effects of low doses of cocaine. They did, however, decrease response rates following administration of cocaine. In contrast, in the present study, comparable doses of the GABA A compounds produced no change in the response rate dose-effect curve of methamphetamine. It is of potential interest that in rats, GABA A positive modulators are more effective at modifying the discriminative effects of methamphetamine, but more effective at modifying the rate effects of cocaine. In monkeys, GABA A agonists and positive modulators also failed to substitute for cocaine (Negus et al., 2000) . In that study, high doses of pentobarbital and triazolam did produce a right shift in the cocaine dose-effect curve, but did not alter the discriminative stimulus effects of D-amphetamine. The monkeys were less sensitive to the rate-decreasing effects of the GABA A compounds than the rats (Negus et al., 2000; Gatch et al., 2003) . It is possible a comparable effect would have been seen in rats had higher doses not completely suppressed responding (Gatch et al., 2003) . It is interesting to note that the GABA reuptake inhibitor tiagabine and the positive modulator triazolam failed to alter the subjective effects of cocaine in human studies (Haga et al., 2003; Lile et al., 2004) .
GABA modulates the actions of dopamine receptors in the central nervous system. For example, the increase in dopamine release induced by methamphetamine is blocked by gamma-vinyl GABA, which irreversibly inhibits degradation of GABA (Gerasimov et al., 1999) , and interneurons in the ventral tegmental area are known to regulate dopamine release in the nucleus accumbens (Xi and Stein, 1998; Rahman and McBride, 2002; Adell and Artigas, 2004) . These findings suggest that release of GABA from GABA-interneurons, or by activating GABA receptors on dopamine neurons in the ventral tegmental area or their terminals in the nucleus accumbens, decreases the activity of those neurons. This would lead to a decrease in DA-mediated effects, such as the methamphetamine discriminative stimulus. However, blockade of GABA receptors would decrease the amount of inhibition, with a concomitant increase in DA activity, but this may not be enough to mimic the increase in DA activity produced by methamphetamine.
This interpretation leads to the prediction that GABA A receptor agonists/positive modulators would at least partially block the discriminative stimulus effects of methamphetamine, whereas GABA A receptor antagonists/ negative modulators would produce small or no substitution for the methamphetamine discriminative stimulus. This is, in fact, what we report in the present study. Similarly, the benzodiazepine clonazepam prevents the development of sensitization to the locomotor effects of methamphetamine (Ito et al., 1997) . In contrast, chlormethiazole, which is usually characterized as a GABA A positive modulator, potentiated the discriminative stimulus effects of methamphetamine (Gasior et al., 2004) . However, the authors suggest that these effects were not mediated by GABA receptors, and chlormethiazole indeed has effects at N-methyl-D-aspartate (NMDA) (Usala et al., 2003) , glycine and purinergic receptors (Pilip et al., 2000) , and acts as a protein kinase inhibitor (Simi et al., 2002) . In the present study, methamphetamine blocks the rate-decreasing effects of GABA A receptor positive modulators and these compounds, in turn, block the subjective effects of methamphetamine. Taken together, these findings indicate that GABA A receptors play a contributing role in modulating the behavioral effects of methamphetamine.
The data from the present study do not provide direct evidence of an interaction of GABAergic compounds at dopaminergic neurons. There is a possibility that the presence of chlordiazepoxide or pentobarbital decrease the perceptibility of methamphetamine through unrelated mechanisms, a phenomenon termed 'perceptual masking' (Gauvin and Young, 1989) .
There is a possibility that the GABA compounds, which are anxiolytic, reduce acute anxiety produced by the methamphetamine at a mechanism unrelated to GABAergic modulation of dopamine release. Currently, there is no clear-cut evidence that methamphetamine produces anxiety. The locomotor activating effects of methamphetamine obscure the results of several anxiety assays, which are activity based (Shimada et al., 1995) . On the other hand, there is a plausible mechanism for a GABA/DA interaction. Until there is more direct evidence that the modulation of the behavioral effects of methamphetamine is mediated by GABA positive modulators or by alterations of anxiety-related effects, or some other neural mechanism, the mechanism for these behavioral effects is speculative.
